Table 3.

Logistic regression of risk of CVD divided by adherence rate of allopurinol and benzbromarone.

	N	No. of CVD	Crude OR (95% C.I.)	p -value	Adjusted OR†(95% C.I.)	p -value
Adherence rate of allopurinol
None	4,101	2,025	Reference		Reference
<0.3	2,908	1,505	1.10 (1.00–1.21)	0.05004	1.15 (1.03–1.28)	0.017
0.3–0.6	266	125	0.91 (0.71–1.17)	0.451	0.95 (0.73–1.23)	0.702
≥0.7	137	51	0.61 (0.43–0.86)	0.006	0.66 (0.46–0.96)	0.030
Adherence rate of benzbromarone
None	1,450	698	Reference		Reference
<0.3	5,072	2,611	1.14 (1.02–1.28)	0.025	1.19 (1.03–1.37)	0.015
0.3–0.6	647	306	0.97 (0.80–1.16)	0.721	1.00 (0.82–1.23)	0.975
≥0.7	243	91	0.65 (0.49–0.85)	0.002	0.68 (0.50–0.91)	0.010

^†Adjusted for allopurinol, benzbromarone, age, sex, hypertension, hyperlipidemia, chronic liver disease, diabetes, COPD, autoimmune disease, statin, and aspirin.